The changing landscape of HIV epidemiology and management
Open Access
- 18 October 2025
- journal article
- review article
- Published by Elsevier in Clinical Medicine
- Vol. 25 (6) , 100520
Abstract
No abstract availableKeywords
Funding Information
- Bill and Melinda Gates Foundation
- National Institute for Health and Care Research
- University of Cambridge
- NIHR Cambridge Biomedical Research Centre
This publication has 39 references indexed in Scilit:
- Lenacapavir: A novel injectable HIV-1 capsid inhibitorInternational Journal of Antimicrobial Agents, 2023
- Lenacapavir (Sunlenca®) for the treatment of HIV-1Trends in Pharmacological Sciences, 2023
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialThe Lancet, 2020
- The Impact of HIV-1 Drug Escape on the Global Treatment LandscapeCell Host & Microbe, 2019
- Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational studyThe Lancet, 2019
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsThe Lancet, 2019
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesThe Lancet, 2018
- Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral TherapyJAMA, 2016
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialThe Lancet, 2016
- Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysisThe Lancet, 2000